AJMC November 9, 2021
An overview of activities at the FDA to promote the use of biosimilars was presented by Jacqueline Corrigan-Curay, JD, MD, principal deputy center director for the Center for Drug Evaluation and Research (CDER) at the FDA.
The FDA sees many ways that the biosimilars development and marketing landscape could be improved, according to Jacqueline Corrigan-Curay, JD, MD, principal deputy center director for the Center for Drug Evaluation and Research (CDER) at the FDA.
Corrigan-Curay spoke about the status of FDA biosimilar initiatives at the GRx+Biosims 2021 meeting of the Association for Accessible Medicines.
Biosimilars, lower-cost versions of originator brand biologics, were introduced in the United States in 2015 and have been making a difference for patients, Corrigan-Curay said. As biosimilars...
Today's Sponsors
Today's Sponsor